Hpv vaccine in cancer
Infectia cu HPV afecteaza atat femeile, cat si barbatii.
De-escalation strategies in the oncological management of HPV-positive oropharyngeal cancer. Source: ORL. Author s : Zahu, Renata; Sturzu, Daniela; Kacso, Gabriel; Ciuleanu, Elisabeta Abstract: HPV-positive oropharyngeal cancers have registered a rising incidence in the last two decades, especially among young nonsmoking adults. Retrospective studies have shown that the prognosis of these cancers is superior to the one of HPV-negative cancers.
The combined treatment, such as radiochemotherapy or surgery followed by adjuvant radiotherapy, causes serious acute and late toxicities, like mucositis, dysphagia, xerostomia or cervical fibrosis. Given the young age group and the better prognosis of HPV-positive cancers, a series of hpv vaccine in cancer strategies to deintensify the treatment have been introduced, such as lower total dose of radiotherapy, omitting chemotherapy or replacing some cytotoxic agents with other less toxic agents.
Mayo Clinic Minute: HPV Vaccine Prevents Cancer
The present paper presents the standard treatment for HPV-positive cancers and a review of the published or still pending studies for de-escalation. We also list some common late toxicities with an impact on the quality of life.
The assessment of parental acceptance of HPV vaccine in a family medicine practice. English Abstract: Introduction.
Copyright of ORL. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy.
Users should refer to the original published version of the material for the full abstract. Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.